HealthPharma & Biotech
Shield Therapeutics PLC

Shield's Feraccru likely to command 'high market share and branded pricing'

Capital Network analyst Emma Ulker assesses recent progress made at Shield Therapeutics PLC (LON:STX) with its lead asset Feraccru.

The drug's approved and marketed in Europe, with a US approval decision pending for July 27.

Feraccru is an oral product absorbed in the gut. It's also an alternative for those unable to tolerate or unresponsive to first-line salt-based oral iron products.

Quick facts: Shield Therapeutics PLC

Price: £1.85

Market: LSE
Market Cap: £216.8 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Shield Therapeutics PLC named herein, including the promotion by the Company of Shield Therapeutics PLC in any Content on the Site, the Company...



Shield Therapeutics' Feraccru drug 'a potential game-changer'

Analyst Riccardo Lowi discusses Shield Therapeutics PLC’s (LON:STX) lead asset Feraccru - a novel and highly differentiated iron formulation, for oral administration, indicated for the treatment of iron deficiency.

on 21/1/19


Director/PDMR Shareholding

4 days, 11 hours ago

Half-year Report

1 week, 6 days ago

Notice of Results

2 weeks, 6 days ago

Second Price Monitoring Extn

3 weeks, 4 days ago

Price Monitoring Extension

3 weeks, 4 days ago

Additional Listing

on 2/7/19

Result of AGM

on 13/6/19

2 min read